Genentech says Phase III IMAgINATION trial shows sefaxersen cuts proteinuria in IgA nephropathy

Genentech reported positive prespecified interim Phase III results for investigational sefaxersen in adults with primary IgA nephropathy.

• The trial met its primary endpoint, showing a meaningful reduction in protein leakage in urine versus placebo, supporting potential disease-slowing benefit.
• Interim findings will be presented at an upcoming medical meeting, with data also set to be shared with regulators.
• The study continues blinded to assess longer-term kidney function outcomes over two years.
• Safety results were consistent with prior reports, with no new safety signals identified.